Fusing an anti-CMV peptide with a cell-penetrating peptide (SynB1) enhanced its ability to enter cells and inhibit cytomegalovirus at lower concentrations.
Lower dose, higher potencySynB1 cell-penetrating peptide enabled anti-CMV activity at reduced concentrations
What the researchers found
Adding the cell-penetrating peptide SynB1 to the ELP-P10 anti-CMV peptide construct enhanced intracellular delivery and antiviral potency at lower concentrations.
Why it matters
CMV infection remains a major threat for transplant recipients and newborns, and current treatments have serious toxicity. More effective peptide delivery could enable safer antiviral therapy.
How the study worked
In vitro study testing SynB1-ELP-P10 fusion construct for cell penetration efficiency and anti-CMV activity compared to ELP-P10 alone.
What this study cannot tell us
In vitro study only — in vivo pharmacokinetics and safety of the triple-fusion construct need to be evaluated. CMV specificity of the enhanced construct requires further characterization.
How to read the evidence
In vitro preclinical study — demonstrates proof of concept for enhanced peptide delivery but far from clinical application.
When this study was published
Published in 2026; builds on prior ELP-P10 in vivo work.
The bigger picture
This demonstrates the broader potential of cell-penetrating peptides to improve drug delivery for peptide therapeutics across many disease areas beyond antivirals.
Questions still open
- Does the SynB1-ELP-P10 construct maintain its improved potency in animal models of CMV infection?
- Could this cell-penetrating peptide approach be applied to other antiviral peptides?
Common questions
What is a cell-penetrating peptide?
Why is CMV hard to treat?
Read the original research
Optimizing delivery of an anti-cytomegalovirus inhibitory peptide using a cell-penetrating peptide.
The Journal of general virology, 107(1)
Citation
Beeton, Komal; Haskell, Jacob P; Mitra, Dipanwita; Taylor, Erin B; Bidwell, Gene L. (2026). Optimizing delivery of an anti-cytomegalovirus inhibitory peptide using a cell-penetrating peptide.. The Journal of general virology, 107(1). https://doi.org/10.1099/jgv.0.002210